Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) announced the pricing of an underwritten public offering of 16,744,187 common shares at $10.75 per share, with gross proceeds of approximately $180 million before underwriting discounts and expenses.

The company granted underwriters a 30-day option to buy up to 2,511,628 additional shares. Jefferies, Goldman Sachs and Citigroup are joint book-runners. The offering is subject to market and other conditions and is being made under an automatic shelf registration on Form S-3ASR.

Positive

• Raised up to approximately $180M gross proceeds
• Underwriters granted a 30-day option for 2,511,628 additional shares
• Sale proceeds will be raised from company-held shares (primary offering)

Negative

• Issuance of 16,744,187 shares may dilute existing shareholders
• Proceeds are reported before underwriting discounts and offering expenses
• Completion subject to market and other conditions; not guaranteed

News Market Reaction – NTLA

-5.72%

35 alerts

-5.72% Session close to close

+11.8% Peak Tracked

-7.2% Trough Tracked

$1.66B Market Cap

1.5x Rel. Volume

In the Apr 29 session, NTLA declined 5.72%, reflecting a notable negative market reaction. Argus tracked a peak move of +11.8% during that session. Argus tracked a trough of -7.2% from its starting point during tracking. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.7% in the session following this news. A negative reaction despite recent gains w...

Analysis

The stock moved -5.7% in the session following this news. A negative reaction despite recent gains would fit a pattern where positive updates, such as the Phase 3 and BLA news that saw -4.33% moves, were followed by selling. An underwritten offering of 16,744,187 shares at $10.75 and potential additional shares via the 30-day option adds dilution over prior share counts of 116,317,060. Investors would also consider how the stock had sat near its 200-day MA before the deal.

Key Figures

Shares offered: 16,744,187 shares Offering price: $10.75 per share Gross proceeds: approximately $180 million +5 more

8 metrics

Shares offered 16,744,187 shares Common stock in underwritten public offering

Offering price $10.75 per share Public offering price for common stock

Gross proceeds approximately $180 million Expected gross proceeds before fees, excluding option exercise

Underwriters’ option 2,511,628 shares 30-day option to purchase additional common shares

Offering amount $150,000,000 Common stock amount in April 27, 2026 424B5 prospectus

Cash balance approximately $517.2 million Cash, cash equivalents and marketable securities as of March 31, 2026

Shares outstanding 116,317,060 shares Common shares outstanding as of December 31, 2025

Short-term move 1.23% Price change in prior 24 hours before offering announcement

Historical Context

5 past events · Latest: Apr 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 27	Phase 3 results	Positive	-4.3%	Positive Phase 3 HAELO topline results for lonvo-z in hereditary angioedema.
Apr 27	Regulatory update	Positive	-4.3%	Initiation of rolling BLA submission to FDA for lonvo-z in HAE.
Apr 24	Data timing news	Positive	-4.3%	Announcement of upcoming global Phase 3 HAELO topline data release date.
Apr 03	Inducement grants	Neutral	+1.3%	Inducement RSU awards to 13 new employees under 2024 Inducement Plan.
Mar 06	Inducement grants	Neutral	+3.4%	Time-based RSU awards totaling 16,500 shares to six new employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent major positive clinical and regulatory milestones were followed by negative price reactions, while routine inducement grant announcements coincided with modest gains.

Recent Company History

Over the last two months, NTLA announced multiple major milestones tied to its in vivo CRISPR program lonvo-z. Positive Phase 3 HAELO topline data and a rolling BLA submission on April 27, 2026 were each followed by a -4.33% move, suggesting the stock sold off despite favorable updates. In contrast, smaller corporate items like inducement grants on April 3 and March 6, 2026 saw modest gains of 1.29% and 3.35%. Today’s common stock offering follows closely on the heels of these clinically important events.

Key Terms

underwritten public offering, common stock, crisper gene editing, automatic shelf registration statement, +2 more

6 terms

underwritten public offering financial

"today announced the pricing of an underwritten public offering of 16,744,187"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

common stock financial

"underwritten public offering of 16,744,187 shares of its common stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

crisper gene editing medical

"revolutionizing medicine leveraging CRISPR gene editing and other core technologies,"

A laboratory technique that acts like precise molecular scissors to cut, remove or change specific parts of DNA inside living cells; it lets scientists alter genes with much greater accuracy than older methods. Investors watch it because successful gene edits can lead to new medicines, agricultural products or diagnostics, while also carrying high research costs, long regulatory reviews, patent disputes and binary clinical trial outcomes that can sharply change a company’s value.

automatic shelf registration statement regulatory

"offered by Intellia pursuant to an automatic shelf registration statement on Form"

An automatic shelf registration statement is a pre-approved filing that companies submit to securities regulators, allowing them to sell new shares or bonds quickly and efficiently when needed. It acts like a standing permit, enabling the company to raise money without going through a lengthy approval process each time, which can be helpful for responding promptly to market opportunities or needs. For investors, it provides transparency about the company's ability to raise funds and signals planning flexibility.

form s-3asr regulatory

"registration statement on Form S-3ASR (File No. 333-275740) that was previously"

Form S-3ASR is a type of SEC registration that lets large, well-known public companies pre-register securities so they can be sold quickly when needed, similar to having a pre-approved credit line they can draw on at short notice. For investors, it matters because it signals a company's readiness to raise cash fast, which can affect share supply and price (dilution) and reveal how easily the company can fund growth or handle short-term needs.

prospectus supplement regulatory

"A preliminary prospectus supplement relating to and describing the terms of the"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the pricing of an underwritten public offering of 16,744,187 shares of its common stock. The shares of common stock are being sold at a public offering price of $10.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $180 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the securities in the offering are to be sold by Intellia. In addition, Intellia has granted the underwriters a 30-day option to purchase up to 2,511,628 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Jefferies, Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The shares of common stock are being offered by Intellia pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-275740) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 24, 2023 and automatically became effective upon filing. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on April 27, 2026. The final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and may be obtained, when available, from: Jefferies LLC by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease.

Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regarding Intellia’s anticipated public offering; uncertainties related to market conditions and statements regarding the timing, size and expected proceeds of the anticipated offering; the safety, tolerability, efficacy, advancement and success of Intellia’s clinical programs; and Intellia’s ability to successfully execute its business and strategic plans, including the advancement, development and commercialization of its product candidates.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies’ evaluation of regulatory filings and other information related to our product candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia’s other product candidates; and risks related to Intellia’s reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly reports on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicommunications.com

FAQ

What did Intellia (NTLA) announce on April 29, 2026 about a stock offering?

Intellia priced an underwritten offering of 16,744,187 common shares at $10.75 each. According to the company, gross proceeds are expected to be about $180 million before underwriting discounts and expenses.

How many additional shares can underwriters buy in the NTLA offering?

Underwriters have a 30-day option to purchase up to 2,511,628 additional shares. According to the company, that option is exercisable at the public offering price less underwriting discounts and commissions.

Who is managing Intellia's April 29, 2026 public offering (NTLA)?

Jefferies, Goldman Sachs and Citigroup are joint book-running managers for the offering. According to the company, prospectus materials were filed and will be available from those firms when final.

Will the NTLA offering guarantees completion or final size and terms?

No, the offering is subject to market and other conditions and may not be completed. According to the company, there is no assurance as to timing, size, or final terms.

How can investors obtain the NTLA offering prospectus filed April 27, 2026?

Investors can request the final prospectus from Jefferies, Goldman Sachs or Citigroup as listed by the company. According to the company, contact details are provided for each manager to obtain documents.